All In Biotech

Drug Trial Radar · NCT03563144

QUILT-3.088: NANT Pancreatic Cancer Vaccine

QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 2018

Primary completion

Dec 30, 2019

Study completion Feb 9, 2022

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Jun 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.

Conditions

  • Metastatic Pancreatic Cancer

Interventions

  • GemcitabineDrug

    Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.

  • Nab-paclitaxelDrug

    NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.

  • Aldoxorubicin HClDrug

    Albumin-binding prodrug of doxorubicin HCl

  • ALT-803Biological

    Recombinant human super agonist interleukin-15 (IL-15) complex

  • ETBX-011Biological

    Ad5 \[E1-, E2b-\]-CEA

  • ETBX-021Biological

    Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine

  • ETBX-051Biological

    Ad5 \[E1-, E2b-\]-Brachyury vaccine

  • ETBX-061Biological

    Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]

  • GI-4000Biological

    Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

  • GI-6207Biological

    CEA yeast vaccine

  • GI-6301Biological

    Brachyury yeast vaccine

  • haNKBiological

    NK-92 \[CD16.158V, ER IL-2\]

  • AvelumabDrug

    Avelumab

  • BevacizumabDrug

    Bevacizumab

  • CapecitabineDrug

    Capecitabine

  • CyclophosphamideDrug

    2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

  • 5-FluorouracilDrug

    5-fluoro-2,4 (1H,3H)-pyrimidinedione

  • LeucovorinDrug

    L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

  • OxaliplatinDrug

    Oxaliplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free SurvivalTime frame: 12 mths

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.